PHOENIX, May 09, 2018 (GLOBE NEWSWIRE) — Dr. Guy Chamberland, Co-Founder, Chief Scientific Officer and Interim-CEO of Tetra-Biopharma Inc. (OTCQB:TBPMF) (TSX-V:TBP) (“the Company”) joined Everett Jolly on Uptick Newswire’s “Stock Day” podcast to provide an update to investors and listeners on some recent company news.
In the interview, Dr. Chamberland described Tetra-Biopharma as a unique and small biopharma that is developing prescription cannabis products through the FDA and Health Canada’s regular drug channels. Currently, one of their products is in phase III clinical trials and is on track to be submitted to regulatory authorities. Chamberland mentions that their hope is to get these products in the hands of consumers as soon as possible. The FDA recently granted the company’s product orphan drug status, which is an FDA designation that allocates special status to drugs and/or biologics being designed for the diagnosis, prevention, or treatment of rare medical conditions. Tetra-Biopharma is proud of this achievement, as orphan drug status can add more scientific credibility to their development process and this designation will help them roll out their products sooner. “This draws attention to our clear focus of bringing drugs to unmet medical conditions, including chronic pain,” says Dr. Chamberland. Updates on their lead compounds are set to be released within the next quarter.While the company has been successful on the drug development side of the business, they have also signed two commercial deals for the Israeli and Portuguese markets. These partnerships will enable Tetra Bio-Pharma to collect upfront payments, milestone payments, and generate a share of the profits in the sales of PPP001. Tetra is active in discussions with companies from around the world interested in commercializing their various products. Once clinical trials conclude, and both the FDA and Health Canada clear the product for distribution, the company hopes to shift focus onto other global markets, including the European and Latin American Markets. Canada is still in the process of legalizing cannabis, and once that happens there will be a better platform for the company to promote the success of their evidence-based products.Dr. Chamberland is confident in the direction the company is headed with regards to the success of their clinical development, financial position, and continued support of their investors. They are hoping to release some news in a few weeks detailing the benefits their products will bring to cancer and chronic pain patients.To hear more about Tetra-Biopharma’s product line, their efforts to combat the opioid crisis, and more updates on their international expansion, listen to the full interview at the link below.https://upticknewswire.com/featured-interview-guy-chamberland-chief-scientific-officer-of-tetra-bio-pharma-inc-2/About Tetra Bio-PharmaFor more information, visit http://tetrabiopharma.com/Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio-pharma industry by regulators, physicians and insurance companies.Safe Harbor StatementCertain statements contained herein are “forward-looking statements,” (as defined in the Private Securities Litigation Reform Act of 1995). Tetra Bio-Pharma cautions that statements and assumptions made in this news release constitute forward-looking statements; the company makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, and other estimates made by management. Actual results could differ from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.About Uptick Newswire
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.Investors Hangout is a proud sponsor of Uptick Newswire’s “Stock Day” Podcast.
Contact InformationDr. Guy Chamberland
Co-Founder, CEO, CSO
Tetra Bio-Pharma Inc.
1 (833) 977-7575
Original story can be found at: http://globenewswire.com/news-release/2018/05/09/1499492/0/en/Dr-Guy-Chamberland-returns-to-Stock-Day-Podcast-with-Everett-Jolly-to-discuss-Tetra-Biopharma.html?f=22&fvtc=5&fvtv=41223728